427 Park Street
Charlottesville, VA 22902
United States
434 297 1000
https://acumenpharm.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 51
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Matt Zuga | CFO & Chief Business Officer | 702.6k | N/D | N/D |
Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 752.95k | N/D | 1971 |
Dr. James Doherty Ph.D. | President & Chief Development Officer | N/D | N/D | 1968 |
Dr. Grant A. Krafft Ph.D. | Co-Founder | 42k | N/D | N/D |
Dr. Caleb E. Finch Ph.D. | Co-Founder | N/D | N/D | N/D |
Dr. William L. Klein Ph.D. | Co-Founder | N/D | N/D | N/D |
Mr. Russell Barton M.S. | Chief Operating Officer | 223.68k | N/D | 1959 |
Ms. Kelly Carranza | Vice President, Finance & Accounting and Corporate Controller | N/D | N/D | N/D |
Ms. Alex Braun M.B.A. | VP & Head of Investor Relations | N/D | N/D | N/D |
Ms. Robyn Moxon M.A. | Associate Director of Communications | N/D | N/D | N/D |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
La calificación ISS Governance QuickScore de Acumen Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 5; Derechos del accionista: 8; Compensación: 9.